MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
BeiGene, Ltd. DPO Ratio 2011-2026 | BGNE
Annual DPO Ratio BeiGene, Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 915 | 44.8 | 58.4 | 93 | 44.5 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 915 | 44.5 | 231 |
Quarterly DPO Ratio BeiGene, Ltd.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 288 | 242 | 299 | - | 290 | 302 | 349 | - | 361 | 397 | 529 | - | 1 K | 1.48 K | 1.14 K | - | 556 | 627 | 705 | - | 1.19 K | 1.65 K | 1.84 K | - | 3.28 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.28 K | 242 | 869 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aptorum Group Limited
APM
|
405 | $ 0.84 | - | $ 4.58 M |  China |
 |
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M |  Canada |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | China |
 |
Amarin Corporation plc
AMRN
|
190 | $ 15.02 | - | $ 6.12 B |  Irlanda |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B |  USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Brickell Biotech
BBI
|
105 | - | -5.38 % | $ 6.06 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Arena Pharmaceuticals
ARNA
|
142 | - | -6.81 % | $ 3.04 B | USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
Baudax Bio
BXRX
|
140 | - | 0.59 % | $ 63 K | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
83.2 | $ 24.27 | - | $ 2.87 B | USA |
 |
Amneal Pharmaceuticals
AMRX
|
21.1 | $ 14.76 | - | $ 4.56 B | USA |
 |
AIkido Pharma
AIKI
|
32.8 K | - | 1.93 % | $ 17.4 M | USA |
 |
Champions Oncology
CSBR
|
64.6 | $ 6.12 | -6.56 % | $ 83.6 M | USA |